Our ELISAs:
developed & manufactured
by Biomedica

FGF23 (Fibroblast Growth Factor 23), a well-known marker for phosphate metabolism, has achieved independent significance in the cardiovascular system [1]. Several large-scale prospective studies have established FGF23 as an independent risk marker for heart failure and mortality [2,3]. There is also growing evidence that FGF-23 levels can predict the response to therapies aimed to reduce [...]

Meet us at the Osteologie 2020, hosted by the Deutsche Gesellschaft für Endokrinologie and the Österreichische Gesellschaft für Knochen- und Mineralstoffwechsel, taking place from 12-14 March 2020 in Salzburg, Austria! We will exhibit together with our partners Fianostics & TAmiRNA at booth #1. Moreover,  we will present out new VEGF-A ELISA at our poster "Novel VEGF-A ELISA [...]

Periostin functions as a ligand for integrins to support adhesion and migration of tumor cells which leads to increased cell survival, invasion, angiogenesis and metastasis in different cancer types including breast cancer (BC).In a recent study using the Biomedica Human Periostin ELISA, Periostin levels were significantly increased in women with primary, non-metastatic breast cancer over [...]

C4d has been regarded as an indirect footprint of an antibody-mediated response against an allograft. While C4d has emerged as a potential marker for antibody-mediated-rejection (AMR) after transplantation over the last decade, its use as a prognostic tool is still under debate. A recent study has shown a positive association of C4d with cardiac allograft [...]